Germany
Japan
United Kingdom
China
Antibodies
View as table Download
Goat Anti-CACNA1C Antibody
| Applications | WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Immunogen | Peptide with sequence C-RARGRPSEEELQD, from the C Terminus of the protein sequence according to NP_000710.5. |
Cacna1c mouse monoclonal antibody, clone N263/31
| Applications | IF, IHC, WB |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
Rabbit Polyclonal Anti-human CaV1.2
| Applications | WB |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
| Immunogen | Peptide VNENTRMYIPEENHQ(C), corresponding to amino acid residues 2-15 of human Cav1.2 (exon 1B). Intracellular, N-terminus. |
CACNA1C pSer1928 rabbit polyclonal antibody, Serum
| Applications | ELISA, IP, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Immunogen | Synthetic peptide derived from C-terminal part of the Human protein containing Phosphoserine 1928 |
Rabbit Polyclonal Anti-CaVpan alpha1
| Applications | WB |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
| Immunogen | Peptide (C)DNFDYLTRDWSILGPHHLD, corresponding to amino acid residues 1506-1524 of rat Cav1.2. Intracellular, C-terminus region. |
Rabbit Polyclonal Anti-CACNA1C Antibody (Internal)
| Applications | IHC |
| Reactivities | Human (Predicted: Monkey) |
| Conjugation | Unconjugated |
| Immunogen | CACNA1C / Cav1.2 antibody was raised against synthetic 16 amino acid peptide from internal region of human CACNA1C / Cav1.2. Percent identity with other species by BLAST analysis: Human, Gibbon (100%); Gorilla, Monkey, Marmoset (94%). |
CACNA1C rabbit polyclonal antibody, Purified
| Applications | ELISA, IHC, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Immunogen | Synthetic peptide derived from C-terminal domain of CAC1C protein. |
Active filters
Filter by
Antibody Hosts
Clonalities
Conjugates
Assay Types
Pathways
- Alzheimer's disease (5)
- Arrhythmogenic right ventricular cardiomyopathy (ARVC) (5)
- Calcium signaling pathway (5)
- Cardiac muscle contraction (5)
- Dilated cardiomyopathy (5)
- GnRH signaling pathway (5)
- Hypertrophic cardiomyopathy (HCM) (5)
- Long-term potentiation (5)
- MAPK signaling pathway (5)
- Type II diabetes mellitus (5)
- Vascular smooth muscle contraction (5)